Current Scenario of 1,3-oxazole Derivatives for Anticancer Activity

Author:

Yan Xinjia1,Wen Jing2,Zhou Lin1,Fan Lei1,Wang Xiaobo1,Xu Zhi3

Affiliation:

1. Department of Pharmacy, The 967th Hospital of Joint Logistic Support Force of PLA, Dalian, China

2. College of Pharmacy, Harbin University of Commerce, Harbin, China

3. College of Pharmaceutical Sciences, Guizhou University of Traditional Chinese Medicine, Guiyang 550025, China

Abstract

Cancer, which has been cursed for human beings for long time is considered as one of the leading causes of morbidity and mortality across the world. In spite of different types of treatments available, chemotherapy is still deemed as a favored treatment for the cancer. Unfortunately, many currently accessible anticancer agents have developed multidrug resistance along with fatal adverse effects. Therefore, intensive efforts have been made to seek for new active drugs with improved anticancer efficacy and reduced adverse effects. In recent years, the emergence of heterocyclic ring-containing anticancer agents has gained a great deal of attention among medicinal chemists. 1,3- oxazole is a versatile heterocyclic compound, and its derivatives possess broad-spectrum pharmacological properties, including anticancer activity against both drug-susceptible, drug-resistant and even multidrug-resistant cancer cell lines through multiple mechanisms. Thus, the 1,3-oxazole moiety is a useful template for the development of novel anticancer agents. This review will provide a comprehensive overview of the recent advances on 1,3-oxazole derivatives with potential therapeutic applications as anticancer agents, focus on the chemical structures, anticancer activity, and mechanisms of action.

Funder

University Nursing Program for Young Scholars with Creative Talents in Heilongjiang Province

Publisher

Bentham Science Publishers Ltd.

Subject

Drug Discovery,General Medicine

Reference153 articles.

1. Vineis P.; Wild C.P.; Global cancer patterns: causes and prevention. Lancet 2014,383(9916),549-557

2. Rojas C.; Casablanca Y.; Chemotherapy, biologic, and immunotherapy breakthroughs in cancer care. Obstet Gynecol Clin North Am 2019,46(1),137-154

3. International Agency for Research on Cancer. Latest global cancer data: Cancer burden rises to 18.1 million new cases and 9.6 million cancer deaths in 2018, Available from: 2018

4. International Agency for Research on Cancer. Cancer Tomorrow. Available from

5. Dickens E.; Ahmed S.; Principles of cancer treatment by chemotherapy. Surgery 2018,36(3),134-148

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3